Get Premium to unlock powerful stock data

Top 5 1st Quarter Trades of Two Seas Capital LP

Author's Avatar
insider
May 14, 2022
Article's Main Image

Two Seas Capital LP recently filed their 13F report for the first quarter of 2022, which ended on 2022-03-31.

The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.

1 READ COURT NEW YORK, NY 10580

As of the latest 13F report, the guru’s equity portfolio contained 12 stocks valued at a total of $119,000,000. The top holdings were HTZ(73.23%), RENN(5.91%), and ABUS(5.49%).

According to GuruFocus data, these were Two Seas Capital LP’s top five trades of the quarter.

Hertz Global Holdings Inc


Two Seas Capital LP reduced their investment in NAS:HTZ by 205,000 shares. The trade had a 3.93% impact on the equity portfolio. During the quarter, the stock traded for an average price of $21.01.

On 05/14/2022, Hertz Global Holdings Inc traded for a price of $18.98 per share and a market cap of $7,821,873,000. The stock has returned 0.00% over the past year.

GuruFocus gives the company a financial strength rating of 3 out of 10 and a profitability rating of 5 out of 10.

In terms of valuation, Hertz Global Holdings Inc has a price-earnings ratio of 9999.00, a price-book ratio of 1.65, a EV-to-Ebitda ratio of 7.52 and a price-sales ratio of 0.40.

Arbutus Biopharma Corp


During the quarter, Two Seas Capital LP bought 1,373,500 shares of NAS:ABUS for a total holding of 2,199,069. The trade had a 3.43% impact on the equity portfolio. During the quarter, the stock traded for an average price of $3.06.

On 05/14/2022, Arbutus Biopharma Corp traded for a price of $2.31 per share and a market cap of $343,562,000. The stock has returned -7.60% over the past year.

GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 3 out of 10.

In terms of valuation, Arbutus Biopharma Corp has a price-book ratio of 2.06, a EV-to-Ebitda ratio of -2.75 and a price-sales ratio of 13.91.

The price-to-GF Value ratio is 0.47, earning the stock a GF Value rank of 4.

Renren Inc


During the quarter, Two Seas Capital LP bought 131,926 shares of NYSE:RENN for a total holding of 322,471. The trade had a 2.42% impact on the equity portfolio. During the quarter, the stock traded for an average price of $21.12.

On 05/14/2022, Renren Inc traded for a price of $27.71 per share and a market cap of $690,487,000. The stock has returned 215.96% over the past year.

GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 3 out of 10.

In terms of valuation, Renren Inc has a price-earnings ratio of 61.57, a price-book ratio of 4.63, a EV-to-Ebitda ratio of -13.83 and a price-sales ratio of 21.03.

The price-to-GF Value ratio is 21.15, earning the stock a GF Value rank of 1.

Roivant Sciences Ltd


During the quarter, Two Seas Capital LP bought 495,862 shares of NAS:ROIV for a total holding of 806,907. The trade had a 2.05% impact on the equity portfolio. During the quarter, the stock traded for an average price of $6.62.

On 05/14/2022, Roivant Sciences Ltd traded for a price of $3.46 per share and a market cap of $2,394,570,000. The stock has returned 0.00% over the past year.

GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, Roivant Sciences Ltd has a price-book ratio of 1.10, a EV-to-Ebitda ratio of 23174.76 and a price-sales ratio of 45.33.

Eagle Pharmaceuticals Inc


The guru sold out of their 45,099-share investment in NAS:EGRX. Previously, the stock had a 1.76% weight in the equity portfolio. Shares traded for an average price of $47.96 during the quarter.

On 05/14/2022, Eagle Pharmaceuticals Inc traded for a price of $44 per share and a market cap of $558,737,000. The stock has returned 8.19% over the past year.

GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 6 out of 10.

In terms of valuation, Eagle Pharmaceuticals Inc has a price-book ratio of 3.19, a EV-to-Ebitda ratio of 578.98 and a price-sales ratio of 3.36.

The price-to-GF Value ratio is 0.80, earning the stock a GF Value rank of 10.


Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.

Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!

This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.

Rating:
0 / 5 (0 votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles